Skip to NavigationSkip to content

Eusa Pharma

EUSA Pharma gets FDA green light to evaluate IL-6 inhibitor siltuximab in COVID-19 patients

Efforts push on to discover an effective treatment for COVID-19 in more than 100 different drug candidates worldwide. EUSA Pharma has joined these efforts with the announcement that the FDA has given the go-ahead for randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate its combination of IL-6 inhibitor siltuximab plus standard of care in hospitalised patients with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS).

EUSA Pharma's COVID-19 drug improves or stabilises respiratory condition in 76% of patients

EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the treatment of serious respiratory complications arising from COVID-19, the leading cause of morbidity and mortality in patients affected by the novel coronavirus.

Siltuximab is an interleukin (IL)-6 targeted monoclonal antibody which has already secured approval from a number of worldwide regulators including the FDA and EMA for the treatment of multicentric Castleman disease (MCD) in patients who are negative for HIV and herpesvirus-8 (HHV-8). 

EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications

Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the novel coronavirus with the launch of a study investigating the efficacy of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, in the treatment of patients with COVID-19 who have developed serious respiratory complications.

The study, sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy, will examine patients currently treated under an ongoing emergency compassionate use protocol, split into two cohorts retrospectively: hospitalised patients prior to admission to an intensive

EUSA Pharma bolsters senior leadership team with two appointments

Published on: 15/05/19

Rare disease and oncology biopharma firm EUSA Pharma has revealed two new additions to its senior leadership team in two newly-created roles: Dr Carsten Thiel as President Europe and Dr Darrel P Cohen as Head of Clinical Development.

EUSA Pharma acquires global rights to oncology support drug

EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.

EUSA Pharma appoints chief executive and director

Published on: 22/04/15

Recently-established UK-based EUSA Pharma has confirmed the appointment of Lee Morley as its chief executive and Dr Göran Ando (pictured) as a non-executive director.

Also Bryan Morton who established EUSA Pharma as founder and first chief executive – will now become executive chairman.

Stephen Stamp joins board at Eusa Pharma

Published on: 07/09/10

Transatlantic specialty company Eusa Pharma has appointed Stephen Stamp to its board as an independent non-executive director.

Stephen has previously held board-level roles at Xanodyne Pharmaceuticals and Shire Pharmaceuticals, and was most recently chief financial officer at K-V Pharmaceutical Company.

Commenting on his appointment, Stephen said, “Having witnessed EUSA’s impressive growth, I am excited to be helping the company achieve its ambitious plans.

Eusa Pharma appoints Iain McGill

Published on: 10/03/10

Iain McGill has joined specialty company Eusa Pharma as international and European president.

He moves to Eusa from Wyeth Pharmaceutical, where he was vice president and global manager for its transplantation business.

Prior to this he was head of Novartis’ Transplantation, Immunology and Infectious Diseases business unit in Canada, and before that a global brand director at Novartis’ headquarters in Switzerland.

He has also held a number of sales and marketing positions of increasing seniority at Novartis and Roche in the UK.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches